Earnings Releases·Nov 9, 2026, 4:22 PM ET

AbCellera — Q3 2026 Earnings Summary

Revenue for Q3 2026 rose to $10.6 million from $9.0 million in Q3 2025, while net loss narrowed to $40.8 million from $57.1 million; total cash and marketable securities exceeded $790 million with liquidity over $890 million.
The company completed a $200 million capital raise, issued approximately 25.7 million new shares, and reported a significant increase in deferred revenue to $83.1 million combined (current and long-term) as of September 30, 2026.
ABCL635 demonstrated positive Phase 2 top-line data for menopausal vasomotor symptoms, with late-stage development and additional clinical trials in hormone suppression populations expected to initiate in 2027.
ABCL575 Phase 1 data met all endpoints for atopic dermatitis, though the company will not advance it past Phase 1, while three new programs (ABCL992, ABCL385, ABCL646) have advanced to IND-enabling activities.
Management confirmed the delivery of all 2026 corporate priorities and noted a reduction in partner-led programs from 44 to 34, with 12 molecules currently in the clinic.